Siirry sisältöön

Asuragen QuantideX NGS tests

Molecular methods ranging from qPCR to NGS to help advance our understanding of cancer

The Asuragen Oncology portfolio uses proprietary molecular chemistry and informatics solutions to deliver critical clinical research insights that drive the evolution of therapy, patient monitoring and precision medicine.

QuantideX NGS DNA Hotspot 21

The QuantideX® NGS DNA Hotspot 21 Kit is an in vitro diagnostic, next-generation sequencing (NGS) panel for the detection of clinically relevant variants across a multitude of tumor types, including non-small cell lung cancer, colorectal cancer, and melanoma. Leveraging our proprietary NGS-in-a-Box™ workflow and Sample-Aware™ bioinformatics quality control solutions, the panel provides a robust and reliable NGS solution for the identification of clinically relevant targets clinicians can trust.

QuantideX NGS RNA Lung Cancer

The QuantideX NGS RNA Lung Cancer Kit is a clinical research tool enabling the simultaneous assessment of fusions, exon skipping, and other expression targets frequently observed in non-small cell lung cancer (NSCLC).

  • The QuantideX NGS DNA Hotspot 21 Kit detects over 1,500 genomic variants within 21 genes
  • End-to-end kitted solution
  • Highly sensitive detection of DNA-based variants
  • Low input (~20ng) of DNA from FFPE
  • Sample-Aware™ bioinformatics analysis and sample quality control
  • Single assay for a broad range of important NSCLC fusion targets
  • All-inclusive reagents from reverse transcription to NGS-ready library
  • Highly sensitive detection of RNA-based fusions
  • Low input (~20ng) of RNA from FFPE
  • Sample-Aware™ bioinformatics analysis and sample quality control

Product is available in the following countries:

  • Finland
  • Estonia
  • Latvia
  • Lithuania

Links and documents

Manufacturer’s product page

Keywords

cancer NGS oncology

Contacts